• Bicycle Therapeutics: Charles Swanton resigned as a Class II director, effective immediately on Aug. 18, 2026.
• Exit also covered his board committee roles and membership on the company’s Clinical Advisory Board.
• Resignation cited personal reasons.
• No disagreement with the company’s operations, policies, or practices was reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099221), on August 20, 2026, and is solely responsible for the information contained therein.